ESMO GI 2026: EMERALD trials paint mixed picture for TACE-immunotherapy combinations in hepatocellular carcinoma
Results from two Phase III trials presented at the 2026 ESMO Gastrointestinal Cancers Congress have…
Browsing: ESMO
ESMO GI 2026: KRYSTAL-10 misses primary endpoints despite improved response rates in KRAS G12C-mutated metastatic colorectal cancer
The combination of adagrasib and cetuximab did not significantly improve progression-free survival (PFS) or overall…
S3 E9 The Oncology Journal Club ESMO 2025 Special: Part 2
ESMO Special Part 2! Are you ready for ESMO Bingo? Welcome to Episode 9 of the third series of The Oncology Journal Club. Dr Kate Clarke takes over hosting duties as Professor Craig Underhill unpacks the GU and lung highlights. With witty commentary and a London Global Cancer Week sneak preview by Professor Christopher Jackson.
Australian-led global study redefines treatment pathway for high-risk prostate cancer
New research findings from the ENZARAD study (ANZUP 1303), led by the Australian and New…
S3E8 The Oncology Journal Club: ESMO 2025 Special Part 1
Are you ready for ESMO Bingo? Welcome to Episode 8 of the third series of The Oncology Journal Club! Our Host Craig Underhill is joined by Dr Kate Clarke and Professor Christopher Jackson to unpack ESMO 2025
ESMO 2025: Study finds COVID-19 mRNA vaccine sparks immune response to cancer
Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100…
ESMO 2025: Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer
A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a…
ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma
The first-in-class YAP-TEAD inhibitor VT3989 continued to be well-tolerated and demonstrated notable initial antitumor activity, particularly…
ESMO 2025: Thymic health linked to immunotherapy response
The health of the thymus – a key part of the body’s immune system -…
ESMO 2025: Men with BRCA1 and BRCA2 gene mutations should get annual prostate cancer screening
Scientists at The Institute of Cancer Research, London, are calling for targeted screening after finding…